Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
FDA Approves Denosumab Biosimilars Stoboclo and Osenvelt

March 4th 2025

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations.

FDA Approved. | Image Credit: Nirusmee - stock.adobe.com
First Insulin Aspart Biosimilar Receives FDA Approval

February 20th 2025

Osteoporosis. | Image Credit: Nisit - stock.adobe.com
Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

February 18th 2025

Insulin. | Image Credit: Sherry Young- stock.adobe.com
Biosimilar Insulin Linked to Lower Prices in Europe

February 12th 2025

FDA approved. | Image Credit: Olivier Le Moal - stock.adobe.com
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra

January 31st 2025

Continuing Medical Education
View All
April 23rd 2025

New and Approved: FDA’s 2024 Drug Lineup

1.5 Credits / General Pharmacy
April 23rd 2025

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

More News

Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds
June 24th 2022

Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds

Laura Joszt, MA
Among a real-world cohort of patients, switching between infliximab biosimilars was effective and well tolerated, although retention was higher among those who had initially started on the originator product.
cutting cost image
June 23rd 2022

Biosimilar Utilization Increased During the OCM and Generated Savings

Laura Joszt, MA
Abstracts presented at the American Society of Clinical Oncology Annual Meeting evaluated biosimilar use in practices participating in the Oncology Care Model (OCM) and estimated the savings as a result of substituting these agents for more expensive reference products.
insulin
June 16th 2022

Canadian Province Successfully Switches Patients to Insulin Glargine Biosimilar

Laura Joszt, MA
As part of the Biosimilars Initiative, British Columbia, Canada, implemented a mandatory switch to biosimilar insulin glargine for patients covered by the province’s drug plan.
elderly patient with doctor
June 10th 2022

Use of Rituximab Biosimilar With CHOP to Treat DLBCL Is Effective, EHA Abstracts Find

Laura Joszt, MA
Using biosimilar rituximab to replace the reference in a common combination regimen to treat diffuse large B-cell lymphoma (DLBCL) results in similar outcomes.
rows of identical vials
June 9th 2022

Studies on Switching Confirm Efficacy of Adalimumab Biosimilars

Laura Joszt, MA
Real-world studies evaluating the safety and efficacy of switching to adalimumab biosimilars from the originator product confirmed the safety and efficacy of the biosimilars ABP 501 and SB5.
fda logo
June 2nd 2022

FDA Approves Fifth Neulasta Biosimilar

Skylar Jeremias
The FDA approval for Fylnetra represents the fifth approval for a biosimilar referencing Neulasta (pegfilgrastim) in the United States.
row of identical vials
June 1st 2022

Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations

Laura Joszt, MA
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version.
Patient and doctor discussing record
May 29th 2022

Patient Experiences, Oncologist Perceptions Differ for Trastuzumab Biosimilar Switch

Laura Joszt, MA
Surveys of patients and oncologists found discrepancies between patient experiences and oncologist perceptions of those experiences during a nonmedical switch to trastuzumab biosimilars.
Sonia Oskouei, PharmD, of Cardinal Health
May 27th 2022

Dr Sonia Oskouei Highlights the Need to Align Incentives to Promote Use of Biosimilars

Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
cutting costs
May 26th 2022

Payer Management Tools and Trends for Biosimilars in the US

Laura Joszt, MA
As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents.
Sonia Oskouei, PharmD, of Cardinal Health
May 16th 2022

Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab Biosimilars

While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Image of a pharmacy
May 12th 2022

Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

Laura Joszt, MA
Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.
Doug Long of IQVIA
May 10th 2022

IQVIA’s Doug Long: Adalimumab Biosimilars Provide More Opportunity for Price Discounts

The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.
health care business and finances
May 4th 2022

340B, Biosimilars, and More in the Future of Specialty Pharmacy

Laura Joszt, MA
Adam Fein, PhD, of Drug Channels Institute, and Doug Long of IQVIA discussed trends in the specialty pharmacy market in the United States.
america graphic
May 3rd 2022

Gottlieb, Fein Discuss COVID-19, Accelerated Approvals, and Drug Pricing at Asembia 2022

Gianna Melillo
Scott Gottlieb, MD, and Adam Fein, PhD, discussed potential fallout of the FDA Aduhelm approval and lessons learned from the COVID-19 pandemic.
Doctor with father and child
April 30th 2022

Biosimilar Education Needed for Pediatric Patients With IBD and Caregivers

Laura Joszt, MA
Not only did a majority of each group say they hadn’t heard of biosimilars, but those who had heard of them had negative perceptions.
Gillian Woollett, MA, Dphil
April 29th 2022

Dr Gillian Woollett Highlights International Markets With Successful Biosimilar Adoption

Skylar Jeremias
Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.
Ryan Haumschild, PharmD, MS, MBA
April 23rd 2022

Ryan Haumschild, PharmD, Explains How Emory Healthcare Will Address the Influx of Humira Biosimilars in 2023

Skylar Jeremias
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.
health care costs
April 21st 2022

Biosimilars Still Used Significantly Less Than Reference Products in Medicare Part D

Laura Joszt, MA
Increased uptake of biosimilars on par with the utilization rates of filgrastim biosimilars could have saved Medicare Part D $84 million in 2019.
FDA approved stamp
April 15th 2022

FDA Approves Third Bevacizumab Biosimilar

Laura Joszt, MA
Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022.
patient in a hospital room
April 12th 2022

Clinical, Economic Benefits of Pegfilgrastim Biosimilars as Prophylactic Against Febrile Neutropenia

Laura Joszt, MA
In patients with intermediate- to high-risk, use of pegfilgrastim biosimilars could optimize management of FN risk.
needle going into a vial
April 7th 2022

Equivalent Safety, Efficacy Between Herceptin and Trastuzumab Biosimilar for Gastric Cancer

Skylar Jeremias
A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.
Chelsee Jensen, PharmD
April 7th 2022

Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product

Skylar Jeremias
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.
Ryan Haumschild, PharmD, MS, MBA
April 2nd 2022

What Can Payers Do to Improve Biosimilar Uptake? Ryan Haumschild, PharmD, Weighs In

Skylar Jeremias
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption.
lines of identical vials
April 2nd 2022

Mayo Clinic Saves $23M Through Biosimilar Adoption Program

Laura Joszt, MA
Implementing changes in a health system to promote biosimilar adoption is not easy, but by implementing a program, there could be substantial savings.
various targets with one higher and larger
March 24th 2022

Infliximab Biosimilar Maintains Outcomes, Remission Status After Switch From Originator

Laura Joszt, MA
Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.
people in suits sitting around a table talking
March 22nd 2022

Panel on Prior Authorization Reveals Role PBMs Play in Biosimilar Uptake in Oncology

Skylar Jeremias
During the recent Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the laser focus on rebates by pharmacy benefit managers (PBMs) may be hindering uptake of biosimilars, thereby keeping some off of formulary lists.
Health care cost image
March 17th 2022

Researchers Find Varied Uptake of Biosimilars in Medicare Part D

Laura Joszt, MA
While filgrastim biosimilars had substantial uptake, there was low uptake of infliximab biosimilars. In addition, there was a lack of price competition.
Julie M. Reed
March 14th 2022

Julie Reed Previews 2022: The Year of Expanded Access to Biosimilars

Skylar Jeremias
As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.
identical vials of medicine lined up
March 9th 2022

Biosimilars Present an Exciting Opportunity for Cigna’s Evernorth, Says CEO Palmer

Laura Joszt, MA
After years, the biosimilars horizon may be here with valuable opportunities to improve patient outcomes and reduce costs, said Eric Palmer, president and CEO of Evernorth.
<1
...
34567891011
...
20>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo